2型糖尿病心血管并发症发病机制的研究进展

doi:10.16352/j.issn.1001-6325.2022.05.008

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (5): 814-817.doi: 10.16352/j.issn.1001-6325.2022.05.008

2型糖尿病心血管并发症发病机制的研究进展

郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉^*

哈尔滨医科大学附属第一医院内分泌科, 黑龙江哈尔滨 150001

收稿日期:2020-11-16 修回日期:2021-04-30 出版日期:2022-05-05 发布日期:2022-04-28
通讯作者: * xiaorongzhan@sina.com
基金资助:
中国医学科学院生物物理研究所科研基金(KJZD-EW-TZ-L05)

Progress on the pathogenesis of cardiovascular complications in patients with type 2 diabetes mellitus

ZHENG Tian-sheng, TONG Xue-wei, ZHANG Yi-tong, ZHU Min, ZHAN Xiao-rong^*

Department of Endocrinology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,China

Received:2020-11-16 Revised:2021-04-30 Online:2022-05-05 Published:2022-04-28
Contact: * xiaorongzhan@sina.com

摘要/Abstract

摘要： 2型糖尿病(T2DM)患者容易出现多种心血管并发症,如冠状动脉粥样硬化性心脏病、高血压、心力衰竭。导致T2DM患者并发心血管疾病的原因和机制错综复杂。有关的机制包括持续性高血糖、胰岛素抵抗、代谢紊乱、氧化应激、心肌纤维化、小血管病变和心脏自主神经病变。

关键词: 2型糖尿病, 心血管并发症, 胰岛素抵抗

Abstract: Patients with type 2 diabetes mellitus(T2DM) trend toward the multiple cardiovascular complications like coronary atherosclerotic heart disease, hypertension, heart failure. The causes and mechanisms leading to cardiovascular disease in patients with type 2 diabetes mellitus are complicated, which include persistent hyperglycemia, insulin resistance, metabolic disorders, oxidative stress, myocardial fibrosis, small vessel disease and cardiac autonomic neuropathy.

Key words: type 2 diabetes mellitus, cardiovascular complications, insulin resistance

中图分类号:

R587

郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉. 2型糖尿病心血管并发症发病机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 814-817.

ZHENG Tian-sheng, TONG Xue-wei, ZHANG Yi-tong, ZHU Min, ZHAN Xiao-rong. Progress on the pathogenesis of cardiovascular complications in patients with type 2 diabetes mellitus[J]. Basic & Clinical Medicine, 2022, 42(5): 814-817.

参考文献

[1] Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017, 128:40-50.
[2] American Diabetes Association.10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43:S111-S134.
[3] Braunwald E.Diabetes, heart failure, and renal dysfunction: the vicious circles[J]. Prog Cardiovasc Dis,2019,62:298-302.
[4] Ioachimescu AG. Diabetes and atherosclerotic cardiovascular disease[J]. Endocrinol Metab Clin North Am, 2018,47:xiii-xiv.doi:10.1016/j.ecl.2017.12.002.
[5] Lee SH, Hwang SM, Kang DH, et al. Brain education-based meditation for patients with hypertension and/or type 2 diabetes: a pilot randomized controlled trial[J]. Medicine, 2019, 98:e15574. doi:10.1097/MD.0000000000015574.
[6] Henning RJ.Type-2 diabetes mellitus and cardiovascular disease[J]. Future Cardiol, 2018, 14:491-509.
[7] Connor T, Martin SD, Howlett KF, et al. Metabolic remodelling in obesity and type 2 diabetes: pathological or protective mechanisms in response to nutrient excess?[J]. Clin Exp Pharmacol Physiol, 2015, 42:109-115.
[8] Julia R, Rong T. Metabolism in cardiomyopathy: every substrate matters[J]. Cardiovasc Res, 2017,113:411-421.
[9] Kozakova M, Morizzo C, Fraser AG, et al.Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus[J]. Cardiovasc Diabetol, 2017,16:78. doi: 10.1186/s12933-017-0557-z.
[10] Vergès B. Is reduction of hyperglycemia associated with a cardiovascular benefit?[J]. Presse Med, 2018,47:764-768.
[11] Kulkarni H, Mamtani M, Blangero J, et al. Lipidomics in the study of hypertension in metabolic syndrome[J]. Curr Hypertens Rep, 2017, 19:7. doi:10.1007/s11906-017-0705-6.
[12] Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese[J]. Hypertens Res, 2017,40:795-806.
[13] Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation[J]. Cardiovasc Diabetol, 2018, 17:57.doi: 10.1186/s12933-018-0703-2.
[14] Wang HH, Lee DK, Liu M, et al. Novel insights into the pathogenesis and management of the metabolic syndrome[J]. Pediatr Gastroenterol Hepatol Nutr, 2020,23:189-230.
[15] Athithan L, Gulsin GS, Mccann GP, et al. Diabetic cardiomyopathy: pathophysiology, theories and evidence to date[J]. World J Diabetes, 2019,10:490-510.
[16] Dhalla NS, Shah AK, Tappia PS. Role of oxidative stress in metabolic and subcellular abnormalities in diabetic cardiomyopathy[J]. Int J Mol Sci, 2020,21:2413. doi:10.3390/ijms21072413.
[17] Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity[J]. Circ Res, 2018, 122:624-638.
[18] Zhang D, Li Y, Heims-Waldron D, et al. Mitochondrial cardiomyopathy caused by elevated reactive oxygen species and impaired cardiomyocyte proliferation[J]. Circ Res, 2018,122:74-87.
[19] Alonso N, Moliner P, Mauricio D. Pathogenesis, clinical features and treatment of diabetic cardiomyopathy[J]. Adv Exp Med Biol, 2018,1067:197-217.
[20] Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus[J]. Arterioscler Thromb Vasc Biol, 2017, 37:191-204.
[21] Jiewen J, Weimin W, Liangying Z, et al. Cardiovascular autonomic neuropathy is an independent risk factor for left ventricular diastolic dysfunction in patients with type 2 Diabetes[J]. Biomed Res Int, 2017, 2017:3270617. doi:10.1155/2017/3270617.
[22] Ningning W, Asadur R, Hirofumi H, et al. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity[J]. Front Endocrinol, 2018, 9:421. doi:10.3389/fendo.2018.00421.
[23] Kang S, Verma S, Hassanabad AF, et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME Results[J]. Can J Cardiol, 2020,36:543-553.
[24] Verma S, Rawat S, Ho KL, et al. Empaglifiozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors[J].JACC Basic Transl Sci, 2018,3:575-587.
[25] Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action[J]. JAMA Cardiol, 2017,2:1025-1029.
[26] Baartscheer A, Schumacher CA, Wust RC, et al. Empaglifiozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits[J].Diabetologia, 2017,60:568-573.

2型糖尿病心血管并发症发病机制的研究进展

Progress on the pathogenesis of cardiovascular complications in patients with type 2 diabetes mellitus

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许晓双, 闵行, 叶月, 郭梦然, 甄东户. 碘与代谢综合征相关性的研究进展[J]. 基础医学与临床, 2022, 42(6): 979-982.
[2]	郑杨, 魏海军, 申嘉陵, 刘润禹, 刘勇, 孙晓磊. MVBs及IL-1β在2型糖尿病大鼠血管钙化中的作用[J]. 基础医学与临床, 2022, 42(2): 208-214.
[3]	孙明玥, 李旭妍, 萨如拉, 李晶晶, 梁浩, 闫朝丽, 苏燕. 2型糖尿病患者红细胞变形能力改变与RBC能量代谢相关[J]. 基础医学与临床, 2021, 41(2): 245-249.
[4]	孙影董世云. 妊娠期代谢综合征对母亲健康及后代生长发育影响的研究进展[J]. 基础医学与临床, 2021, 41(10): 1518-1522.
[5]	刘宁, 张伟华. 糖尿病合并高血压加重血管病变的研究进展[J]. 基础医学与临床, 2020, 40(7): 990-994.
[6]	卢亚男, 刘丽俊, 李伟. GA/HbA1c比值与2型糖尿病合并非酒精性脂肪肝相关[J]. 基础医学与临床, 2020, 40(12): 1636-1639.
[7]	杨波熊婉媛铁宝霞蔡小玲哈小琴. 糖尿病与细胞焦亡[J]. 基础医学与临床, 2019, 39(7): 1061-1065.
[8]	朱伟郑世霞柯琳秋汪毅陈琼科夏道涵王红漫. SFRP5基因对小鼠肝癌细胞Hepa1-6糖代谢的影响[J]. 基础医学与临床, 2018, 38(9): 1268-1273.
[9]	邱维张薇陶建瓴王海云郑法雷李雪梅. 倍半萜内酯减轻糖尿病小鼠胰岛素抵抗及早期肾损伤[J]. 基础医学与临床, 2018, 38(9): 1292-1297.
[10]	王丽萍宋斌戴燕陈晖张真稳闫彩凤潘云龙. 多种脂源性细胞因子与2型糖尿病患者胰岛素抵抗相关[J]. 基础医学与临床, 2017, 37(9): 1247-1250.
[11]	刘滢贺桂琼覃万翔罗敏汪克建. β淀粉样蛋白及代谢酶类在阿茨海默病和糖尿病模型小鼠脑内的表达[J]. 基础医学与临床, 2017, 37(5): 653-657.
[12]	由继君赵丹玉. 槲皮素促进软脂酸诱导EA.hy926细胞合成IRS2[J]. 基础医学与临床, 2017, 37(2): 249-250.
[13]	罗春步世忠王福艳. 葛根素治疗2型糖尿病的药理机制和临床进展[J]. 基础医学与临床, 2016, 36(11): 1582-1585.
[14]	杨久琳刁腾月张岩. db/db小鼠心、肾RAS组分的分子表达[J]. 基础医学与临床, 2015, 35(3): 341-344.
[15]	王晓晶聂敏孙梅励. MicroRNAs与葡萄糖稳态研究进展[J]. 基础医学与临床, 2014, 34(9): 1272-1276.